Related Experiment Video
Updated: Aug 23, 2025
08:48
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
3.0K
SARS-CoV-2-on-Chip for Long COVID Management.
Jayesh Cherusseri1, Claire Mary Savio2, Mohammad Khalid1,3
1Graphene & Advanced 2D Materials Research Group (GAMRG), School of Engineering and Technology, Sunway University, No. 5, Jalan Universiti, Bandar Sunway, Petaling Jaya 47500, Malaysia.
Biosensors
|October 27, 2022
Summary
The development of on-site biosensors offers a practical solution for diagnosing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These portable devices provide rapid, cost-effective, and accessible testing, overcoming limitations of traditional laboratory methods.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Infectious Disease Diagnostics
Background:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents significant global health challenges due to its high mortality and prolonged progression.
- Current diagnostic methods like reverse transcription polymerase chain reaction (RT-PCR) are effective but limited by cost, complexity, time, and laboratory dependency.
Purpose of the Study:
- To review recent advancements in biosensor technology for the management of coronavirus disease (COVID).
- To highlight the transition of SARS-CoV-2 biosensors from laboratory settings to on-site applications.
- To explore the potential of intelligent and economical biosensor platforms for public health emergency preparedness.
Main Methods:
- Review of current literature on biosensor development for SARS-CoV-2 detection.
- Analysis of various biosensor platforms, including point-of-care and lab-on-chip devices.
- Evaluation of the shift towards portable, on-site diagnostic technologies.
Main Results:
- Biosensors offer a promising alternative to traditional RT-PCR for SARS-CoV-2 diagnosis.
- On-site and lab-on-chip biosensors reduce the need for extensive human resources and laboratory infrastructure.
- Advancements enable intelligent and economical operation for remote and accessible testing.
Conclusions:
- Biosensors represent a paradigm shift in infectious disease diagnostics, particularly for managing public health emergencies like COVID.
- Portable biosensor technology facilitates remote access and reduces the burden on healthcare systems.
- These innovations pave the way for near-future diagnostic solutions for rapid response to health crises.
